-
1
-
-
0032545933
-
Potent and specifi c genetic interference by double-stranded RNA in Caenorhabditis elegans
-
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specifi c genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
-
(1998)
Nature
, vol.391
, pp. 806-811
-
-
Fire, A.1
Xu, S.2
Montgomery, M.K.3
Kostas, S.A.4
Driver, S.E.5
Mello, C.C.6
-
2
-
-
0035942736
-
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
-
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.
-
(2001)
Nature
, vol.411
, pp. 494-498
-
-
Elbashir, S.M.1
Harborth, J.2
Lendeckel, W.3
Yalcin, A.4
Weber, K.5
Tuschl, T.6
-
4
-
-
77957925036
-
A status report on RNAi therapeutics
-
Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, et al. A status report on RNAi therapeutics. Silence 2010; 8: 1-14.
-
(2010)
Silence
, vol.8
, pp. 1-14
-
-
Vaishnaw, A.K.1
Gollob, J.2
Gamba-Vitalo, C.3
Hutabarat, R.4
Sah, D.5
Meyers, R.6
-
5
-
-
84952978803
-
Progress in the delivery of siRNA therapeutics: Potential in uveal melanoma
-
Gollob JA, Bumcrot D, Toudjarska I, Bastian BC, Sah DW, Vaishnaw AK. Progress in the delivery of siRNA therapeutics: potential in uveal melanoma. Drugs Future 2011; 36: 229-39.
-
(2011)
Drugs Future
, vol.36
, pp. 229-239
-
-
Gollob, J.A.1
Bumcrot, D.2
Toudjarska, I.3
Bastian, B.C.4
Sah, D.W.5
Vaishnaw, A.K.6
-
6
-
-
34548735210
-
Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes
-
Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, et al. Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A 2007; 104: 12982-7.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 12982-12987
-
-
Rozema, D.B.1
Lewis, D.L.2
Wakefield, D.H.3
Wong, S.C.4
Klein, J.J.5
Roesch, P.L.6
-
7
-
-
34848918210
-
Impact of tumor-specifi c targeting on the biodistribution and effi cacy of siRNA nanoparticles measured by multimodality in vivo imaging
-
Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specifi c targeting on the biodistribution and effi cacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007; 104: 15549-54.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 15549-15554
-
-
Bartlett, D.W.1
Su, H.2
Hildebrandt, I.J.3
Weber, W.A.4
Davis, M.E.5
-
8
-
-
25444482607
-
Sequence-specifi c knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma
-
Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specifi c knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65: 8984-92.
-
(2005)
Cancer Res
, vol.65
, pp. 8984-8992
-
-
Hu-Lieskovan, S.1
Heidel, J.D.2
Bartlett, D.W.3
Davis, M.E.4
Triche, T.J.5
-
9
-
-
77951132901
-
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
-
Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-70.
-
(2010)
Nature
, vol.464
, pp. 1067-1070
-
-
Davis, M.E.1
Zuckerman, J.E.2
Choi, C.H.3
Seligson, D.4
Tolcher, A.5
Alabi, C.A.6
-
10
-
-
34447122735
-
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
-
Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 2007; 7: 47-55.
-
(2007)
Clin Exp Med
, vol.7
, pp. 47-55
-
-
Koldehoff, M.1
Steckel, N.K.2
Beelen, D.W.3
Elmaagacli, A.H.4
-
11
-
-
35148815670
-
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
-
Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007; 25: 1149-57.
-
(2007)
Nat Biotechnol
, vol.25
, pp. 1149-1157
-
-
Wolfrum, C.1
Shi, S.2
Jayaprakash, K.N.3
Jayaraman, M.4
Wang, G.5
Pandey, R.K.6
-
12
-
-
77954243341
-
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
-
Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010; 18: 1357-64.
-
(2010)
Mol Ther
, vol.18
, pp. 1357-1364
-
-
Akinc, A.1
Querbes, W.2
De, S.3
Qin, J.4
Frank-Kamenetsky, M.5
Jayaprakash, K.N.6
-
13
-
-
33646185371
-
RNAi-mediated gene silencing in non-human primates
-
Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-4.
-
(2006)
Nature
, vol.441
, pp. 111-114
-
-
Zimmermann, T.S.1
Lee, A.C.2
Akinc, A.3
Bramlage, B.4
Bumcrot, D.5
Fedoruk, M.N.6
-
14
-
-
50149101511
-
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
-
Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008; 105: 11915-20.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 11915-11920
-
-
Frank-Kamenetsky, M.1
Grefhorst, A.2
Anderson, N.N.3
Racie, T.S.4
Bramlage, B.5
Akinc, A.6
-
15
-
-
65649085603
-
Confi rming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
-
Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, et al. Confi rming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009; 119: 661-73.
-
(2009)
J Clin Invest
, vol.119
, pp. 661-673
-
-
Judge, A.D.1
Robbins, M.2
Tavakoli, I.3
Levi, J.4
Hu, L.5
Fronda, A.6
-
16
-
-
79959958353
-
Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products
-
Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem 2011; 18: 3136-55.
-
(2011)
Curr Med Chem
, vol.18
, pp. 3136-3155
-
-
Wahl, O.1
Oswald, M.2
Tretzel, L.3
Herres, E.4
Arend, J.5
Efferth, T.6
-
17
-
-
52749097817
-
Progress on kinesin spindle protein inhibitors as anticancer agents
-
Zhang Y, Xu W. Progress on kinesin spindle protein inhibitors as anticancer agents. Anticancer Agents Med Chem 2008; 8: 698-704.
-
(2008)
Anticancer Agents Med Chem
, vol.8
, pp. 698-704
-
-
Zhang, Y.1
Xu, W.2
-
18
-
-
20144389695
-
Sequence-specifi c potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7
-
Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specifi c potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11: 263-70.
-
(2005)
Nat Med
, vol.11
, pp. 263-270
-
-
Hornung, V.1
Guenthner-Biller, M.2
Bourquin, C.3
Ablasser, A.4
Schlee, M.5
Uematsu, S.6
-
19
-
-
22344454846
-
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
-
Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23: 457-62.
-
(2005)
Nat Biotechnol
, vol.23
, pp. 457-462
-
-
Judge, A.D.1
Sood, V.2
Shaw, J.R.3
Fang, D.4
McClintock, K.5
MacLachlan, I.6
-
21
-
-
0027050420
-
Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma
-
Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D, et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774-81.
-
(1992)
Cancer Res
, vol.52
, pp. 6774-6781
-
-
Huang, S.K.1
Mayhew, E.2
Gilani, S.3
Lasic, D.D.4
Martin, F.J.5
Papahadjopoulos, D.6
-
22
-
-
0023280158
-
Fate and behavior of liposomes in vivo: A review of controlling factors
-
Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987; 3: 123-93.
-
(1987)
Crit Rev Ther Drug Carrier Syst
, vol.3
, pp. 123-193
-
-
Senior, J.H.1
-
23
-
-
0034000453
-
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
-
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
-
(2000)
J Control Release
, vol.65
, pp. 271-284
-
-
Maeda, H.1
Wu, J.2
Sawa, T.3
Matsumura, Y.4
Hori, K.5
-
25
-
-
42549088324
-
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
-
Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2008; 26: 257-64.
-
(2008)
Invest New Drugs
, vol.26
, pp. 257-264
-
-
Tang, P.A.1
Siu, L.L.2
Chen, E.X.3
Hotte, S.J.4
Chia, S.5
Schwarz, J.K.6
-
26
-
-
79955627902
-
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
-
Burris HA, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, et al. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest New Drugs 2011; 29: 467-72.
-
(2011)
Invest New Drugs
, vol.29
, pp. 467-472
-
-
Burris, H.A.1
Jones, S.F.2
Williams, D.D.3
Kathman, S.J.4
Hodge, J.P.5
Pandite, L.6
-
28
-
-
9144247189
-
Therapeutic silencing of an endogenous gene by systemic administration of modifi ed siRNAs
-
Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modifi ed siRNAs. Nature 2004; 432: 173-8.
-
(2004)
Nature
, vol.432
, pp. 173-178
-
-
Soutschek, J.1
Akinc, A.2
Bramlage, B.3
Charisse, K.4
Constien, R.5
Donoghue, M.6
-
29
-
-
80052174164
-
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention
-
Szebeny J, Muggia F, Gabizo A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011; 63: 1020-30.
-
(2011)
Adv Drug Deliv Rev
, vol.63
, pp. 1020-1030
-
-
Szebeny, J.1
Muggia, F.2
Gabizo, A.3
Barenholz, Y.4
-
30
-
-
14644415949
-
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
-
Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23: 1028-43.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1028-1043
-
-
Rini, B.I.1
Small, E.J.2
-
31
-
-
37549006796
-
Clinical and biological signifi cance of vascular endothelial growth factor in endometrial cancer
-
Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, et al. Clinical and biological signifi cance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13: 7487-95.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 7487-7495
-
-
Kamat, A.A.1
Merritt, W.M.2
Coffey, D.3
Lin, Y.G.4
Patel, P.R.5
Broaddus, R.6
-
32
-
-
79958037593
-
New treatment options for patients with advanced neuroendocrine tumors
-
Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treatment Options Oncol 2011; 12: 136-48.
-
(2011)
Curr Treatment Options Oncol
, vol.12
, pp. 136-148
-
-
Chan, J.A.1
Kulke, M.H.2
-
33
-
-
77953915105
-
Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/ solitary fi brous tumor
-
Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/ solitary fi brous tumor. C urr Opin Oncol 2010; 22: 351-5.
-
(2010)
C urr Opin Oncol
, vol.22
, pp. 351-355
-
-
Park, M.S.1
Ravi, V.2
Araujo, D.M.3
-
34
-
-
33846478656
-
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
-
O'Connor JPB, Jackson A, Parker GJM, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-95.
-
(2007)
Br J Cancer
, vol.96
, pp. 189-195
-
-
O'Connor, J.P.B.1
Jackson, A.2
Parker, G.J.M.3
Jayson, G.C.4
-
35
-
-
29144470346
-
Real-time quantifi cation of microRNAs by stem-loop RT-PCR
-
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantifi cation of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33; e179.
-
(2005)
Nucleic Acids Res
, vol.33
-
-
Chen, C.1
Ridzon, D.A.2
Broomer, A.J.3
Zhou, Z.4
Lee, D.H.5
Nguyen, J.T.6
-
36
-
-
0030568858
-
Increased expression of vascular endothelial growth factor and its receptors, fl t-1 and KDR/fl k-1, in regenerating rat liver
-
Mochida S, Ishikawa K, Inao M, Shibuya M, Fujiwara K. Increased expression of vascular endothelial growth factor and its receptors, fl t-1 and KDR/fl k-1, in regenerating rat liver. Biochem Biophys Res Comm 1996; 226: 176-9.
-
(1996)
Biochem Biophys Res Comm
, vol.226
, pp. 176-179
-
-
Mochida, S.1
Ishikawa, K.2
Inao, M.3
Shibuya, M.4
Fujiwara, K.5
-
37
-
-
0035013447
-
Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats
-
Shimizu H, Miyazaki M, Wakabayashi Y, Mitsuhashi N, Kato A, Ito H, et al. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol 2001; 34: 683-9.
-
(2001)
J Hepatol
, vol.34
, pp. 683-689
-
-
Shimizu, H.1
Miyazaki, M.2
Wakabayashi, Y.3
Mitsuhashi, N.4
Kato, A.5
Ito, H.6
-
38
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell cancer
-
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell cancer. N Engl J Med 2007; 356: 125-34.
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
Siebels, M.6
-
39
-
-
79851482955
-
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
-
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-13.
-
(2011)
N Engl J Med
, vol.364
, pp. 501-513
-
-
Raymond, E.1
Dahan, L.2
Raoul, J.L.3
Bang, Y.J.4
Borbath, I.5
Lombard-Bohas, C.6
-
40
-
-
70350002279
-
Adverse effects of anticancer agents that target the VEGF pathway
-
Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-77.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 465-477
-
-
Chen, H.X.1
Cleck, J.N.2
-
41
-
-
34548068395
-
Infl ammatory breast cancer: Dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience
-
Thukral A, Thomasson DM, Chow CK, Eulate R, Wedam SB, Gupta SN, et al. Infl ammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology 2007; 244: 727-35.
-
(2007)
Radiology
, vol.244
, pp. 727-735
-
-
Thukral, A.1
Thomasson, D.M.2
Chow, C.K.3
Eulate, R.4
Wedam, S.B.5
Gupta, S.N.6
-
42
-
-
24944515034
-
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamics measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study
-
Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamics measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 5464-73.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5464-5473
-
-
Liu, G.1
Rugo, H.S.2
Wilding, G.3
McShane, T.M.4
Evelhoch, J.L.5
Ng, C.6
-
43
-
-
79957949444
-
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
-
Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011; 29: 2259-65.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2259-2265
-
-
Aghajanian, C.1
Sill, M.W.2
Darcy, K.M.3
Greer, B.4
McMeekin, D.S.5
Rose, P.G.6
-
44
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
|